deltatrials
Completed PHASE2 NCT00028288

Study of Daclizumab in Patients With Chronic, Persistent Asthma

A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Daclizumab in Patients With Chronic, Persistent Asthma

Sponsor: Facet Biotech

Conditions Asthma
Interventions Daclizumab
Updated 6 times since 2017 Last updated: Mar 9, 2012 Started: Sep 30, 2001 Primary completion: Dec 31, 2003 Completion: Dec 31, 2003

A PHASE2 clinical study on Asthma, this trial is completed. The trial is conducted by Facet Biotech and has accumulated 6 data snapshots since 2001. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE2

▶ Show 1 earlier version

  1. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2

    First recorded

Sep 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Facet Biotech
Data source: Facet Biotech

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bloomington, United States, Dallas, United States, Denver, United States, Easton, United States, Lake Oswego, United States, Long Beach, United States, Madison, United States, Miami, United States, Milwaukee, United States, Minneapolis, United States and 7 more location s